MX2015016589A - Composicion oral veterinaria con gabapentina. - Google Patents

Composicion oral veterinaria con gabapentina.

Info

Publication number
MX2015016589A
MX2015016589A MX2015016589A MX2015016589A MX2015016589A MX 2015016589 A MX2015016589 A MX 2015016589A MX 2015016589 A MX2015016589 A MX 2015016589A MX 2015016589 A MX2015016589 A MX 2015016589A MX 2015016589 A MX2015016589 A MX 2015016589A
Authority
MX
Mexico
Prior art keywords
composition
gabapentin
sorbitan
combinations
total weight
Prior art date
Application number
MX2015016589A
Other languages
English (en)
Inventor
Samuel CHAIT AUERBACH Jaime
PÉREZ NAVARRETE Cliserio
Original Assignee
Samuel CHAIT AUERBACH Jaime
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel CHAIT AUERBACH Jaime filed Critical Samuel CHAIT AUERBACH Jaime
Priority to MX2015016589A priority Critical patent/MX2015016589A/es
Priority to PCT/MX2016/000124 priority patent/WO2017095214A1/es
Priority to US16/076,578 priority patent/US10610498B2/en
Priority to EP16871109.1A priority patent/EP3384907A4/en
Publication of MX2015016589A publication Critical patent/MX2015016589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica veterinaria sólida, de administración oral que comprende: a) fármaco seleccionado de gabapentina y/o fluoxetina o una sal farmacéuticamente aceptable de los mismos, preferentemente gabapentina o una sal aceptable del mismo en una concentración de 10 a 1000 mg; b) de 10% al 80% del peso total de la composición de al menos una sal de silicio seleccionado de manera preferente de dióxido de silicio, dióxido de silicio coloidal, silicato de calcio, silicato de magnesio o combinaciones de los mismos; c) de 1% al 20% del peso total de la composición de al menos un éster polioxietilenado de sorbitán, seleccionado de manera preferente de monolaurato de sorbitán, monooleato de sorbitán y trioleato de sorbitan, o combinaciones de los mismos; y d) uno o más excipientes farmacéuticamente aceptables; tal que se prepara de manera óptima como un producto farmacéutico veterinario que presenta seguridad y eficacia en animales mamíferos, preferentemente en animales de compañia.
MX2015016589A 2015-12-02 2015-12-02 Composicion oral veterinaria con gabapentina. MX2015016589A (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2015016589A MX2015016589A (es) 2015-12-02 2015-12-02 Composicion oral veterinaria con gabapentina.
PCT/MX2016/000124 WO2017095214A1 (es) 2015-12-02 2016-12-02 Composición oral veterinaria con gabapentina
US16/076,578 US10610498B2 (en) 2015-12-02 2016-12-02 Oral veterinary composition with gabapentin
EP16871109.1A EP3384907A4 (en) 2015-12-02 2016-12-02 VETERINARY ORAL COMPOSITION CONTAINING GABAPENTINE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015016589A MX2015016589A (es) 2015-12-02 2015-12-02 Composicion oral veterinaria con gabapentina.

Publications (1)

Publication Number Publication Date
MX2015016589A true MX2015016589A (es) 2017-06-01

Family

ID=58797399

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016589A MX2015016589A (es) 2015-12-02 2015-12-02 Composicion oral veterinaria con gabapentina.

Country Status (4)

Country Link
US (1) US10610498B2 (es)
EP (1) EP3384907A4 (es)
MX (1) MX2015016589A (es)
WO (1) WO2017095214A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3900715A1 (en) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Synergistic admixtures of gabapentin and ketoprofen, pharmaceutical compositions and their medical use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69832712T2 (de) 1997-09-08 2006-06-22 Warner-Lambert Company Llc Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
US20030013740A1 (en) * 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
AU3216600A (en) 1999-03-10 2000-09-28 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
MX2007014422A (es) 2005-05-20 2008-02-11 Pfizer Ltd Combinaciones sinergicas de farmacos atiinflamatorios con ligandos alfa-delta.
EP2029116A4 (en) * 2006-06-19 2012-07-04 Accu Break Technologies Inc SECURE PHARMACEUTICAL FORMS
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
US8791105B2 (en) 2010-07-14 2014-07-29 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration

Also Published As

Publication number Publication date
US20190046475A1 (en) 2019-02-14
US10610498B2 (en) 2020-04-07
EP3384907A1 (en) 2018-10-10
EP3384907A4 (en) 2019-06-05
WO2017095214A1 (es) 2017-06-08

Similar Documents

Publication Publication Date Title
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
EP3207931A3 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
EA201792345A1 (ru) Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
IN2015DN00528A (es)
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
PH12016500414B1 (en) Solid preparation containing choline alfoscerate and method for preparing same
MX2015016589A (es) Composicion oral veterinaria con gabapentina.
EA201792237A1 (ru) Фармацевтические составы
MX2022001802A (es) Metodos para incrementar la biodisponibilidad de medicamentos farmaceuticos y de venta libre.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
GB2530226A (en) Chewable tablet
CL2020003153A1 (es) Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016)
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
PH12020500120A1 (en) Pharmaceutical compositions
CY1120282T1 (el) Φαρμακευτικη συνθεση κιτρικης σιλδεναφιλης με την μορφη ενος εναιωρηματος για εκ του στοματος χρηση
MX2018011685A (es) Proceso para formulaciones solidas de mesalazina.
PH12016502540A1 (en) Pharmaceutical dosage forms